Deep Learning, Head & Neck Squamous Cell Carcinoma
Conditions
Keywords
Head & neck squamous cell carcinoma, Deep Learning
Brief summary
Based on multimodal data, the investigators establish a dynamic deep learning model to conduct prognostic risk assessment for patients and recommend the 'most suitable' treatment/follow-up regimen after radical treatment, assisting clinicians in improving homogenized evaluation levels and achieving individualized precision therapy, thereby providing scientific evidence for the currently widely debated selection of postoperative adjuvant therapy in locally advanced head and neck squamous cell carcinoma patients.
Detailed description
This clinical study is an observational bidirectional study. A retrospective cohort is used to train the model for recurrent risk prediction and adjuvant treatment decision-making, while a prospective cohort serves as an external validation set to verify the model performance.
Interventions
None listed
Sponsors
Nanfang Hospital, Southern Medical University
Peking University Shenzhen Hospital
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 years. * Patients diagnosed and treated at Nanfang Hospital, Southern Medical University or its cooperative hospitals between January 2017 and December 2025. * Patients who either seek medical treatment after June 2022 or sought medical treatment before that but have not lost contact with the hospital for more than 1 year are required to sign the informed consent form voluntarily. * Newly diagnosed head and neck squamous cell carcinoma (HNSCC) confirmed by histopathology. * Locally advanced disease without distant metastasis. * Complete clinical data (including patient demographics, tumor characteristics, treatment details, and prognostic variables). * Availability of MRI, CT, or PET-CT images before and after radical treatment.
Exclusion criteria
* History of or coexisting secondary malignancies. * Lack of definitive radical treatment. * Absence of baseline or follow-up imaging (MRI/CT/PET-CT). * Investigator-determined unsuitability for study participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year progress-free survival | 2 years | From the initiation of treatment to the date of tumor progression (including local recurrence, regional lymph node metastasis, and distant metastasis) or tumor-related death, whichever occurs first. If no progression event was observed by the cutoff date of follow-up, the last follow-up date was used. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 2-year overall survival | 2 years | From the initiation of treatment to the date of death from any cause or the cutoff date of follow-up. |
| 2-year recurrence-free survival | 2 years | From the initiation of treatment to the date of first local tumor recurrence, regional lymph node metastasis, or tumor-related death, whichever occurs first. If no such event was observed by the cutoff date of follow-up, the last follow-up date was used. |
Countries
China
Outcome results
None listed